Therefore, oligomerization between JAK2 fusions and their endogenous JAK2 fusion partner may contribute to leukemogenesis by impairing the tumor-suppressive function of the WT JAK2 fusion partner (Medves and Demoulin, 2012). The gene discussed is JAK2; the disease is neoplasm.